N/A
Completed N=80
Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine
Brachial Plexus Anesthesia
Source: ClinicalTrials.gov NCT02393677 ↗
Enrolled (actual)
80
Serious AEs
0.0%
Results posted
Nov 2015
Primary outcomePrimary: Duration of Analgesia — 413.73; 197.35 minutes
Summary
80 American Society of Anesthesiologists (ASA) grade I-II patients, 18-60 years old,scheduled for elective upper limb orthopaedic surgery under supraclavicular brachial plexus block, were included in this prospective study. The patients were randomly assigned to group R (Ropivacaine alone) and group RD (Ropivacaine and dexmedetomidine) (40 patients in each group). Group R received Ropivacaine 0.50% (30 cc) + placebo and group RD received Ropivacaine 0.50% (30 cc) + dexmedetomidine 1 µg/kg.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Duration of Analgesia |
413.73; 197.35 | — |
| SECONDARY Onset of Sensory Block |
— | — |
| SECONDARY Onset of Motor Block |
— | — |
| SECONDARY Duration of Motor Block |
— | — |
Eligibility Criteria
Inclusion Criteria
- 80 ASA Grade I and II patients of either sex, aged 18-60 years, undergoing various orthopaedic surgeries on the upper limb under supraclavicular brachial plexus block.
Exclusion Criteria
- Patient refusal
- Patients with chronic pain (pain lasting more than 12 weeks)
- Those using chronic analgesic medications (opioid, non steroidal anti-inflammatory drugs, anticonvulsants, antidepressants)
- Coagulopathy
- History of brachial plexus injury
- Allergy to the study drugs
- Patients taking other medications with α-adrenergic blocking effect
- Hepatic or renal insufficiency
- Systemic infection or infection at the site of injection, and shoulder surgery.
Data sourced from ClinicalTrials.gov (NCT02393677). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.